Patents by Inventor Samuel Kaye
Samuel Kaye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240309019Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: December 6, 2023Publication date: September 19, 2024Inventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Patent number: 12060347Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: GrantFiled: December 16, 2020Date of Patent: August 13, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Patent number: 12037324Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: GrantFiled: July 11, 2022Date of Patent: July 16, 2024Assignees: Bristol-Myers Squibb Company, Université de MontréalInventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
-
Patent number: 11932658Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and Ri, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: GrantFiled: January 6, 2021Date of Patent: March 19, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20230045357Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: ApplicationFiled: July 11, 2022Publication date: February 9, 2023Applicants: Université de Montréal, Bristol-Myers Squibb CompanyInventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
-
Patent number: 11407733Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: GrantFiled: June 28, 2017Date of Patent: August 9, 2022Assignees: Bristol-Myers Squibb CompanyInventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
-
Publication number: 20210188877Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: January 6, 2021Publication date: June 24, 2021Inventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20210163465Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: December 16, 2020Publication date: June 3, 2021Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Patent number: 10730868Abstract: Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: GrantFiled: July 13, 2017Date of Patent: August 4, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Qinghong Fu, Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20190315774Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: July 13, 2017Publication date: October 17, 2019Inventors: XIAOJUN Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20190300520Abstract: Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: July 13, 2017Publication date: October 3, 2019Inventors: Qinghong Fu, Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20190292176Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: July 13, 2017Publication date: September 26, 2019Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20190202808Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: ApplicationFiled: June 28, 2017Publication date: July 4, 2019Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
-
Patent number: 4022585Abstract: A method for sealing and protecting the surface of advanced composite materials against moisture and other contaminants. Advanced composite materials, which comprise high strength fibers such as graphite or boron fibers in a resin matrix such as epoxy or polyimide resins, suffer a performance loss when subjected to moisture. In high vacuum environments, such as in many outer space applications, resin binder outgassing may cause contamination of the overall device. Significant dimensional changes occur when these composite structures are used in environments with widely varying humidity levels. The disclosed method of preventing such degradation basically comprises the steps of undercoating the surface with a metal coating, fluxing the undercoat, forming a layer of molten metal on the undercoat then solidifying the metal topcoating. A seal coating substantially impervious to water and highly resistant to dimensional changes and corrosion results.Type: GrantFiled: April 21, 1975Date of Patent: May 10, 1977Assignee: General Dynamics CorporationInventor: Samuel Kaye